Schering Partners with ChemDiv in Medicinal Chemistry
News Sep 15, 2005
ChemDiv, Inc. has announced that it has entered into a medicinal chemistry research partnership with Schering AG, Berlin, Germany.
The collaboration between the companies will last a minimum of two years, with an extension clause dependent upon meeting defined milestones under the contract.
Under the terms of the collaboration, ChemDiv will apply its expertise in small molecule chemistry to support the ongoing medicinal chemistry programs at Schering.
Schering will have access to a wide range of services including chemistry development, synthesis of hit and lead series, as well as scale up production of advanced intermediates.
ChemDiv will utilize its global logistics platform to support the collaboration with on time formatting and distribution services.
Alexander Kiselyov, VP of Global Chemistry at ChemDiv, Inc. commented, "We are delighted to expand our relationship with Schering AG under the new collaboration agreement.”
“We see this as an acknowledgement of the success of ChemDiv's discovery services. ChemDiv will continue to commit its expertise and resources to add value to Schering's discovery programs."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE